LLY

1,071.32

+0.71%↑

JNJ

208.42

+0.07%↑

ABBV

226.26

+0.83%↑

UNH

333.8

+2.13%↑

AZN

91.77

+1.24%↑

LLY

1,071.32

+0.71%↑

JNJ

208.42

+0.07%↑

ABBV

226.26

+0.83%↑

UNH

333.8

+2.13%↑

AZN

91.77

+1.24%↑

LLY

1,071.32

+0.71%↑

JNJ

208.42

+0.07%↑

ABBV

226.26

+0.83%↑

UNH

333.8

+2.13%↑

AZN

91.77

+1.24%↑

LLY

1,071.32

+0.71%↑

JNJ

208.42

+0.07%↑

ABBV

226.26

+0.83%↑

UNH

333.8

+2.13%↑

AZN

91.77

+1.24%↑

LLY

1,071.32

+0.71%↑

JNJ

208.42

+0.07%↑

ABBV

226.26

+0.83%↑

UNH

333.8

+2.13%↑

AZN

91.77

+1.24%↑

Search

Omnicell Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

46.81 0.8

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

45.74

Max

47.13

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-177K

5.5M

Pardavimai

20M

311M

P/E

Sektoriaus vid.

100.628

76.798

Pelnas, tenkantis vienai akcijai

0.51

Pelno marža

1.758

Darbuotojai

3,600

EBITDA

524K

31M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+1.18% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

585M

2B

Ankstesnė atidarymo kaina

46.01

Ankstesnė uždarymo kaina

46.81

Naujienos nuotaikos

By Acuity

50%

50%

167 / 374 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

Omnicell Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-18 23:54; UTC

Karštos akcijos

Stocks to Watch: Nike, Cassava Sciences, KB Home

2025-12-18 23:51; UTC

Uždarbis

Nike Sales Tick Up in 2Q; China Weakness Persists -- Update

2025-12-18 23:39; UTC

Pagrindinės rinkos jėgos

Cassava Sciences Shares Fall After FDA Places Hold on Epilepsy Drug Trial

2025-12-18 22:57; UTC

Įsigijimai, susijungimai, perėmimai

TikTok Signs Agreement for Sale of U.S. Unit, Axios Reports, Citing a Memo

2025-12-18 21:40; UTC

Uždarbis

Nike Sales Tick Up, But China Weakness Persists

2025-12-18 23:45; UTC

Rinkos pokalbiai

Gold Steady, Supported by Fed Rate-Cut Prospects -- Market Talk

2025-12-18 23:37; UTC

Rinkos pokalbiai
Uždarbis

Nike 2Q Results Fail to Convince Investors of Recovery -- Market Talk

2025-12-18 23:36; UTC

Rinkos pokalbiai

Nikkei May Rise, Tracking Wall Street's Rally -- Market Talk

2025-12-18 23:03; UTC

Įsigijimai, susijungimai, perėmimai

Mitsubishi Materials: Impact on Consolidated Results for FY Ending March 2026 Likely to be Immaterial

2025-12-18 23:02; UTC

Įsigijimai, susijungimai, perėmimai

Mitsubishi Materials: To Acquire 4,448 Common Shares, 13,771 Preferred Shares of Co.

2025-12-18 23:00; UTC

Įsigijimai, susijungimai, perėmimai

Mitsubishi Materials: Investment to Strengthen Recovery Network in U.S.

2025-12-18 22:59; UTC

Įsigijimai, susijungimai, perėmimai

Mitsubishi Materials: Investment to Contribute to Expanding Collection Volume of Secondary Raw Material

2025-12-18 22:58; UTC

Įsigijimai, susijungimai, perėmimai

SpaceX Could Go Public by Merging With EchoStar. It Isn't a Crazy Idea. -- Barrons.com

2025-12-18 22:57; UTC

Įsigijimai, susijungimai, perėmimai

Mitsubishi Materials: Elemental USA E-Waste Operates E-Waste Recycling Business in U.S.

2025-12-18 22:56; UTC

Įsigijimai, susijungimai, perėmimai

Mitsubishi Materials: To Acquire Portion of Shares of Elemental USA E-Waste & ITAD

2025-12-18 22:55; UTC

Uždarbis

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

2025-12-18 21:59; UTC

Uždarbis

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

2025-12-18 21:50; UTC

Rinkos pokalbiai
Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2025-12-18 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-12-18 21:35; UTC

Uždarbis

FedEx's Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

2025-12-18 21:31; UTC

Uždarbis

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

2025-12-18 21:15; UTC

Uždarbis

Nike 2Q Europe, Middle East & Africa Rev $3.39B >NKE

2025-12-18 21:15; UTC

Uždarbis

Nike 2Q Greater China Rev Down 17% >NKE

2025-12-18 21:15; UTC

Uždarbis

Nike 2Q EPS 53c >NKE

2025-12-18 21:15; UTC

Uždarbis

Nike 2Q Apparel Rev $3.91B >NKE

2025-12-18 21:15; UTC

Uždarbis

Nike 2Q Equipment Rev $550M >NKE

2025-12-18 21:15; UTC

Uždarbis

Nike 2Q N Amer Rev $5.63B >NKE

2025-12-18 21:15; UTC

Uždarbis

Nike 2Q Footwear Rev $7.66B >NKE

2025-12-18 21:15; UTC

Uždarbis

Nike 2Q Asia Pacific & Latin America Rev Down 4% >NKE

2025-12-18 21:15; UTC

Uždarbis

Nike 2Q Greater China Rev $1.42B >NKE

Akcijų palyginimas

Kainos pokytis

Omnicell Inc Prognozė

Kainos tikslas

By TipRanks

1.18% į viršų

12 mėnesių prognozė

Vidutinis 46.33 USD  1.18%

Aukščiausias 50 USD

Žemiausias 43 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Omnicell Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

4 ratings

3

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

24.23 / 30.44Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bearish Evidence

Vidutinės trukmės periodas

Strong Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

167 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Omnicell Inc

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
help-icon Live chat